1. Home
  2. AERT vs SCYX Comparison

AERT vs SCYX Comparison

Compare AERT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeries Technology Inc.

AERT

Aeries Technology Inc.

HOLD

Current Price

$0.56

Market Cap

27.9M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.64

Market Cap

24.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AERT
SCYX
Founded
2012
1999
Country
Singapore
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
24.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
AERT
SCYX
Price
$0.56
$0.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
181.3K
561.5K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$69,346,000.00
$2,932,000.00
Revenue This Year
N/A
$167.73
Revenue Next Year
N/A
$290.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$0.57
52 Week High
$2.67
$1.49

Technical Indicators

Market Signals
Indicator
AERT
SCYX
Relative Strength Index (RSI) 46.39 43.52
Support Level $0.53 $0.65
Resistance Level $0.65 $0.72
Average True Range (ATR) 0.06 0.05
MACD 0.00 0.01
Stochastic Oscillator 44.29 42.38

Price Performance

Historical Comparison
AERT
SCYX

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: